Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:TARA OTCMKTS:VICP NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$2.45+2.9%$1.91$1.05▼$5.17$264.11M0.26985,761 shs65,133 shsTARAProtara Therapeutics$5.36-0.7%$3.88$1.78▼$10.48$206.79M1.53365,341 shs1,389 shsVICPSSGI$1.77$1.77$1.25▼$3.00$57.30M4.27N/AN/AZURAZura Bio$3.42+0.6%$2.63$0.97▼$4.96$222.36M0.25870,031 shs1,274 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+18.41%+31.49%+24.61%+41.67%+96.69%TARAProtara Therapeutics-2.88%+0.75%+69.28%+59.29%+168.66%VICPSSGI0.00%0.00%0.00%0.00%+17.22%ZURAZura Bio+0.89%-5.03%+70.85%+101.18%-29.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$2.45+2.9%$1.91$1.05▼$5.17$264.11M0.26985,761 shs65,133 shsTARAProtara Therapeutics$5.36-0.7%$3.88$1.78▼$10.48$206.79M1.53365,341 shs1,389 shsVICPSSGI$1.77$1.77$1.25▼$3.00$57.30M4.27N/AN/AZURAZura Bio$3.42+0.6%$2.63$0.97▼$4.96$222.36M0.25870,031 shs1,274 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+18.41%+31.49%+24.61%+41.67%+96.69%TARAProtara Therapeutics-2.88%+0.75%+69.28%+59.29%+168.66%VICPSSGI0.00%0.00%0.00%0.00%+17.22%ZURAZura Bio+0.89%-5.03%+70.85%+101.18%-29.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 2.90Moderate Buy$8.71255.83% UpsideTARAProtara Therapeutics 2.86Moderate Buy$19.60265.67% UpsideVICPSSGI 0.00N/AN/AN/AZURAZura Bio 2.75Moderate Buy$11.60239.18% UpsideCurrent Analyst Ratings BreakdownLatest VICP, ZURA, TARA, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.0010/14/2025ACRSAclaris TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/14/2025ZURAZura BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TARAProtara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/30/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.009/27/2025ACRSAclaris TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TARAProtara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ZURAZura BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/19/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.008/15/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.008/15/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$16.79M15.80N/AN/A$1.44 per share1.70TARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/AVICPSSGIN/AN/AN/AN/A($0.06) per shareN/AZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.37N/AN/AN/A-802.03%-34.01%-24.18%11/5/2025 (Estimated)TARAProtara Therapeutics-$44.60M-$1.62N/AN/AN/AN/A-36.87%-33.85%11/11/2025 (Estimated)VICPSSGI-$1.18M-$0.04N/A∞N/AN/AN/AN/AN/AZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-49.11%-40.06%11/6/2025 (Estimated)Latest VICP, ZURA, TARA, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025TARAProtara Therapeutics-$0.39N/AN/AN/AN/AN/A11/6/2025Q3 2025ZURAZura Bio-$0.19N/AN/AN/AN/AN/A11/5/2025Q3 2025ACRSAclaris Therapeutics-$0.13N/AN/AN/A$1.59 millionN/A8/14/2025Q2 2025ZURAZura Bio-$0.19-$0.17+$0.02-$0.17N/AN/A8/11/2025Q2 2025TARAProtara Therapeutics-$0.43-$0.35+$0.08-$0.35N/AN/A8/7/2025Q2 2025ACRSAclaris Therapeutics-$0.13-$0.13N/A-$0.13$1.34 million$1.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/AVICPSSGIN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.883.88TARAProtara TherapeuticsN/A12.8112.82VICPSSGIN/AN/AN/AZURAZura BioN/A8.408.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%TARAProtara Therapeutics38.13%VICPSSGIN/AZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%TARAProtara Therapeutics12.50%VICPSSGI5.98%ZURAZura Bio22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.33 million102.27 millionOptionableTARAProtara Therapeutics3038.58 million33.76 millionOptionableVICPSSGI232.37 million30.44 millionNot OptionableZURAZura Bio365.02 million50.65 millionOptionableVICP, ZURA, TARA, and ACRS HeadlinesRecent News About These CompaniesZura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 21 at 5:32 AM | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Sees Significant Growth in Short InterestOctober 18, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Zura Bio (NASDAQ:ZURA)October 16, 2025 | americanbankingnews.comZura Bio's (ZURA) Sell (D-) Rating Reiterated at Weiss RatingsOctober 14, 2025 | marketbeat.comLeerink Partners Reaffirms Their Buy Rating on Zura Bio (ZURA)October 13, 2025 | theglobeandmail.comZura Bio CEO Takes Medical Leave, Interim AppointedOctober 10, 2025 | msn.comIs Zura Bio’s (ZURA) Executive Severance Plan Hinting at Leadership Stability or Looming Funding Shifts?October 4, 2025 | finance.yahoo.comChardan Capital Maintains Zura Bio (ZURA) Buy RecommendationOctober 1, 2025 | msn.comZura Bio Implements Executive Severance Benefit PlanSeptember 30, 2025 | tipranks.comSeptember 2025's Promising Penny Stocks RevealedSeptember 30, 2025 | finance.yahoo.comChardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)September 30, 2025 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by BrokeragesSeptember 26, 2025 | marketbeat.comZura Bio Unveils Updated Corporate PresentationSeptember 4, 2025 | tipranks.comZura Bio price target lowered to $2 from $3 at H.C. WainwrightAugust 19, 2025 | msn.comZura Bio price target lowered to $16 from $17 at OppenheimerAugust 15, 2025 | msn.comZura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate UpdatesAugust 14, 2025 | businesswire.comRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31, 2025 | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVICP, ZURA, TARA, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$2.45 +0.07 (+2.90%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Protara Therapeutics NASDAQ:TARA$5.36 -0.04 (-0.74%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.SSGI OTCMKTS:VICP$1.77 0.00 (0.00%) As of 10/20/2025Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.Zura Bio NASDAQ:ZURA$3.42 +0.02 (+0.59%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
